Provides clinical practice guidelines for growth hormone and IGF-I treatment in children and adolescents with specific growth disorders.
The taskforce suggests that the recommendations be applied in clinical practice with consideration of the evolving literature and the risks and benefits to each individual patient. In many instances, careful review highlights areas that need further research.
Grimberg et al. (2016) studied this question.